Polyrizon Ltd.
- Open
- 11.30
- Day high
- 11.78
- Day low
- 11.28
- Prev close
- 11.42
- Volume
- 4K
- Mkt cap
- $25M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 1.2
- P/S
- —
- Yield
- —
- Per share
- —
Polyrizon Ltd. (PLRZ) is a Healthcare company listed on NASDAQ. The stock is up 188% over the past year.
Polyrizon Ltd. (PLRZ) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
PLRZ earnings date, history & EPS estimates
PLRZ insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Mar 31, 2026 | Carmel Lirondirector | Sell | 100 | $11.00 |
| Mar 31, 2026 | Izraeli Tomerdirector, officer: Chief Executive Officer | Sell | 3,900 | $10.90 |
| Mar 31, 2026 | Turgeman Tidhardirector, officer: Chief Technology Officer | Sell | 2,917 | $10.90 |
Source: PLRZ SEC Form 4 filings, latest Mar 31, 2026. For informational purposes only — not investment advice.
See the full PLRZ insider & 13F page →Polyrizon Ltd. company profile
Overview
Polyrizon Ltd. (NASDAQ:PLRZ) is an Israeli biotechnology company founded in 2005 and headquartered in Ra'anana, Israel. The company went public on October 29, 2024, making it one of the newest entrants to the public markets in the biotech sector. Polyrizon specializes in developing innovative medical device hydrogels delivered through nasal spray formulations designed to create protective barriers against viruses and allergens. As a pre-revenue biotech company, Polyrizon is currently in the development phase of its product pipeline, focusing on respiratory protection and allergy management solutions.
Business
Polyrizon operates in the biotechnology sector, specifically within the medical devices and respiratory health market. The company develops hydrogel-based nasal sprays that function as protective barriers against airborne pathogens and allergens. Hydrogels are water-absorbing polymer networks that can be engineered to have specific properties, and in Polyrizon's case, they are formulated to create a physical barrier on nasal epithelial tissue. The nasal cavity serves as the primary entry point for many respiratory viruses and allergens. Traditional approaches to respiratory protection often involve masks or systemic medications, but Polyrizon's approach focuses on creating a localized barrier directly at the point of entry. Their hydrogel technology is designed to coat the nasal passages, potentially preventing pathogens and allergens from making contact with the underlying tissue where infection or allergic reactions typically begin. Polyrizon's current product pipeline consists of three main candidates: PL-14 targets nasal allergies and is designed to block allergens from reaching nasal tissue, potentially providing relief for individuals suffering from seasonal or environmental allergies. PL-15 was developed specifically for COVID-19 protection, aiming to create a barrier against SARS-CoV-2 virus particles. PL-16 focuses on influenza prevention, targeting common flu viruses that typically enter through the respiratory tract. The company operates as a single-segment business focused entirely on nasal spray medical device development, with no current revenue diversification across multiple product lines or markets.
Revenue model
Polyrizon's business model is typical of early-stage biotech companies developing medical devices. The company currently generates no revenue and operates on a research and development model funded by investor capital. Once products receive regulatory approval, the company would likely monetize through product sales to healthcare providers, pharmacies, and potentially direct-to-consumer channels. The target customer base would include healthcare systems, retail pharmacies, and individual consumers seeking respiratory protection or allergy relief. Given the nature of nasal sprays, the products could potentially be sold as over-the-counter medical devices, which would expand the addressable market significantly compared to prescription-only medications. Several factors could impact Polyrizon's future margins and commercial success. Regulatory approval timelines and costs represent the most significant near-term challenge, as medical device approval processes can be lengthy and expensive. Manufacturing scale and cost efficiency will be critical once commercialization begins, as hydrogel production costs and supply chain management will directly impact gross margins. Competition from established pharmaceutical companies developing similar barrier technologies or alternative respiratory protection methods could pressure pricing and market share. Seasonal demand patterns may affect revenue predictability, particularly for allergy-related products that typically see higher demand during specific times of the year. Healthcare reimbursement policies and insurance coverage decisions could significantly impact market adoption and pricing power, especially in markets where consumers expect insurance coverage for medical interventions.
Competitive moat
Polyrizon's competitive moat appears relatively narrow at this early stage of development. The company's primary potential advantage lies in its specialized hydrogel formulation technology and any intellectual property protection around its specific nasal barrier approach. However, the barrier-to-entry in nasal spray development is not particularly high, and larger pharmaceutical companies with significantly more resources could potentially develop competing technologies. The nasal spray and respiratory protection market faces competition from multiple angles. Established pharmaceutical companies like Johnson & Johnson, Pfizer, and others have extensive experience in nasal spray formulations and could rapidly develop competing products. Traditional allergy medications such as antihistamines and corticosteroid nasal sprays already address the allergy market that PL-14 targets. Alternative respiratory protection methods including improved mask technologies, air filtration systems, and other preventive approaches could reduce demand for nasal barrier products. The company's moat strength is further limited by the fact that hydrogel technology itself is well-established, and the specific application to nasal barriers, while innovative, may not provide sustainable competitive advantages. Regulatory approval could provide temporary market exclusivity, but this protection is typically time-limited and may not prevent competitors from developing alternative approaches to achieve similar outcomes. Without strong patent protection or unique manufacturing capabilities, Polyrizon may struggle to maintain pricing power once larger competitors enter the market.
Risks & safety
Polyrizon presents a high-risk investment profile typical of pre-revenue biotech companies, with limited margin of safety for investors. • Cash position and burn rate: The company holds $2.5 million in cash as of Q4 2024, with an annual cash burn of approximately $1.1 million based on 2024 operating cash flow. This provides roughly 2-2.5 years of runway at current burn rates. • Debt and solvency: Minimal debt burden with debt-to-equity ratio of 0.0 as of latest reporting, indicating no significant leverage risk. Current ratio of 10.2 shows strong short-term liquidity position. • Valuation metrics: Traditional valuation metrics are not meaningful for a pre-revenue company. The enterprise value to EBITDA ratio is negative due to losses, and there are no sales multiples to evaluate. • Other considerations: The company's recent IPO in October 2024 likely provided sufficient capital for near-term operations, but future funding needs will depend on development progress and regulatory timelines. The biotech sector's inherent binary risk profile means success or failure in clinical trials and regulatory approval could result in significant stock price volatility.
Recent development
Based on available financial data, Polyrizon's recent development has been focused on transitioning from a private to public company. The company completed its initial public offering in October 2024, which significantly improved its financial position from the precarious state observed in 2023 when it had minimal cash reserves and high current liabilities. The most notable development has been the substantial improvement in the company's balance sheet following the IPO. Cash and short-term investments increased from just $4,000 at the end of 2023 to $2.5 million by the end of 2024, while total current liabilities decreased from $502,000 to $261,000. This transformation eliminated the company's previous solvency concerns and provided adequate funding for continued research and development activities. The company's research and development spending has remained relatively consistent, with annual losses of approximately $1.5 million in 2024 compared to $600,000 in 2023, suggesting increased investment in product development activities. However, without detailed earnings call transcripts, specific information about clinical trial progress, regulatory submission timelines, or strategic partnerships is not available from the financial data alone. The company appears to be in the early stages of its public company journey, focusing on advancing its three-product pipeline through development phases while building the infrastructure necessary for eventual commercialization.
PLRZ company profile · for informational purposes only — not investment advice.
Track PLRZ with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free